Abstract 640P
Background
Multiple myeloma (MM) is frequently diagnosed among elderly, who are not commonly considered eligible to the autologous stem cell transplantation (ASCT). This observational retrospective analysis aimed to describe, from the perspective of the Italian National Health Service (INHS), newly MM diagnosed subjects, their direct healthcare costs and rate of ASCT, from 2015 to 2019.
Methods
From ReS (Ricerca e Salute) database, collecting a portion of Italian administrative healthcare data, adults with main/secondary diagnosis of MM (ICD9-CM code: 203.0x) during the index hospitalization from 2015 to 2018 (accrual period) and without any MM diagnosis within the previous years (until 2013) were selected. Gender, age and comorbidities were described. Healthcare costs charged to the INHS and the rate of subjects experiencing ASCT (Kaplan Meier curves) were analyzed within a variable follow-up (up to 4 years).
Results
From 2015 to 2018, 1,648 newly MM diagnosed patients were identified: males were 52%; mean age was 71±12. The most frequent comorbidities were arterial hypertension (73%), dyslipidemia (31%) and asthma/chronic obstructive pulmonary disease (30%). On average, within one follow-up year, the INHS spent €28,360 per patient (€5,813 for index hospitalization): hospitalizations accounted for 52% (of which 60% for chemotherapy sessions), pharmaceuticals for 42% (of which 70% for immunotherapy use), outpatient specialist care for 6%. Alongside a substantial loss of analyzable patients (282 subjects the 4th year) and the decrease of the mean overall annual cost (€15,352 the 4th year), the trend showed increasing expenditure for pharmaceuticals (91% the 4th year), due to the increasingly higher immunotherapy use, while decreasing costs for hospitalizations (3.2% the 4th year), mainly due to the absence of index costs. Within four years, 212 underwent ASCT, with a 1-year cumulative probability of 14%. On average, patients undergoing ASCT were 58±8 years old.
Conclusions
This Italian real-world analysis took a picture of newly MM diagnosed patients in Italy in terms of healthcare resource consumption, from the perspective of the INHS, and showed the use of ASCT mainly among younger subjects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sanofi Italia.
Disclosure
All authors have declared no conflicts of interest.